Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in SLXNW held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Polar Asset Management Partners Inc. | 743K | $16K | 0.0% | 230.152% | 0.00% |
| 2 | Oasis Management Co Ltd. | 11K | $14K | 0.0% | 3.440% | 0.00% |
| 3 | LINDEN ADVISORS LP | 338K | $7K | 0.0% | 104.477% | 0.00% |
| 4 | ARISTEIA CAPITAL LLC | 237K | $5K | 0.0% | 73.226% | 0.00% |
| 5 | Clear Street Group Inc. | 219K | $4K | -0.1% | 67.721% | 0.00% |
| 6 | GOLDMAN SACHS GROUP INC | 123K | $3K | +1.9% | 38.229% | 0.00% |
| 7 | SECURITY BENEFIT LIFE INSURANCE CO /KS/ | 150K | $2K | 0.0% | 46.434% | 0.00% |
| 8 | JANE STREET GROUP, LLC | 75K | $2K | 0.0% | 23.189% | 0.00% |
| 9 | PICTON MAHONEY ASSET MANAGEMENT | 57K | $1K | 0.0% | 17.699% | 0.00% |
| 10 | Context Capital Management, LLC | 51K | $1K | 0.0% | 15.844% | 0.00% |
| 11 | TENOR CAPITAL MANAGEMENT Co., L.P. | 50K | $1K | 0.0% | 15.478% | 0.00% |
| 12 | GABELLI & Co INVESTMENT ADVISERS, INC. | 38K | $774 | 0.0% | 11.810% | 0.00% |
| 13 | Neuberger Berman Group LLC | 32K | $641 | 0.0% | 9.767% | 0.00% |
| 14 | GABELLI FUNDS LLC | 30K | $619 | 0.0% | 9.440% | 0.00% |
| 15 | DUPONT CAPITAL MANAGEMENT CORP | 33K | $406 | 0.0% | 10.061% | 0.00% |
| 16 | STIFEL FINANCIAL CORP | 16K | $325 | 0.0% | 4.953% | 0.00% |
| 17 | Saba Capital Management, L.P. | 12K | $242 | 0.0% | 3.695% | 0.00% |
| 18 | Kepos Capital LP | 100K | $2 | 0.0% | 30.956% | 0.00% |
| 19 | Mint Tower Capital Management B.V. | 25K | $1 | 0.0% | 7.739% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SLXNW — a direct measure of their conviction.
Filings activity in SLXNW during Q1 2026, grouped by how each filer changed its position.
No new institutional buyers in this quarter.
7 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 19 | 14% | 199.99% | +0.00 pp | $0M | 25% |
| Q4 2025 | 22 | +0.0% | 199.99% | +0.00 pp | $0M | 35% |
| Q3 2025 | 22 | 4.3% | 199.99% | +0.00 pp | $0M | +21% |
| Q2 2025 | 23 | 15% | 199.99% | +0.00 pp | $0M | 47% |
| Q1 2025 | 27 | +3.8% | 199.99% | +0.00 pp | $0M | +133% |
| Q4 2024 | 26 | 19% | 199.99% | +0.00 pp | $0M | 13% |
| Q3 2024 | 32 | — | 199.99% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying SLXNW stock.
Based on Q1 2026 13F filings, institutional ownership of Silexion Therapeutics Ltd. stands at 200.0%, held across 19 reporting institutions.
Polar Asset Management Partners Inc. is the largest reported institutional holder of SLXNW, with approximately 743,475 shares worth $0.00B as of Q1 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of SLXNW, including JANE STREET GROUP, LLC.
Our composite Smart Money Score for SLXNW is 30 out of 100 (Bearish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
0 institutions opened new positions in SLXNW during Q1 2026, while 3 fully exited. 0 added to existing positions and 18 trimmed.
SLXNW institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of -3 holders.
The top 10 institutions account for 93.2% of all reported 13F value in SLXNW, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Silexion Therapeutics Ltd. (SLXNW) Institutional Ownership